Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
17.37
+0.34 (2.00%)
Nov 21, 2024, 12:59 PM EST - Market open
Pacira BioSciences Analyst Ratings
Total Analysts
10
Consensus Rating
Buy
Price Target
$26.60
Upside
+53.14%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold Maintains $25 → $17 | Hold | Maintains | $25 → $17 | -2.13% | Nov 12, 2024 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +26.66% | Nov 8, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $15 → $16 | Hold | Maintains | $15 → $16 | -7.89% | Nov 7, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $14 → $15 | Hold | Maintains | $14 → $15 | -13.64% | Oct 4, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $15 → $18 | Strong Buy | Maintains | $15 → $18 | +3.63% | Sep 24, 2024 |
| Truist Securities | Truist Securities | Strong Buy → Strong Sell Downgrades $30 → $8 | Strong Buy → Strong Sell | Downgrades | $30 → $8 | -53.94% | Aug 13, 2024 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $37 → $14 | Buy → Hold | Downgrades | $37 → $14 | -19.40% | Aug 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $57 → $39 | Strong Buy | Maintains | $57 → $39 | +124.53% | Aug 12, 2024 |
| Needham | Needham | Strong Buy Maintains $43 → $22 | Strong Buy | Maintains | $43 → $22 | +26.66% | Aug 12, 2024 |
| JP Morgan | JP Morgan | Buy → Sell Downgrades $45 → $10 | Buy → Sell | Downgrades | $45 → $10 | -42.43% | Aug 12, 2024 |
| Raymond James | Raymond James | Buy Maintains $41 → $37 | Buy | Maintains | $41 → $37 | +113.01% | Jul 31, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $42 → $37 | Buy | Maintains | $42 → $37 | +113.01% | Jul 31, 2024 |
| Needham | Needham | Strong Buy Reiterates $43 | Strong Buy | Reiterates | $43 | +147.55% | Jul 31, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $45 → $30 | Strong Buy | Maintains | $45 → $30 | +72.71% | Jul 25, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $42 | Buy | Maintains | $42 | +141.80% | Jul 3, 2024 |
| Barclays | Barclays | Buy → Hold Downgrades $38 → $25 | Buy → Hold | Downgrades | $38 → $25 | +43.93% | Jul 3, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.